Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report
Gilly, F.N.; Beaujard, A.; Bienvenu, J.; Trillet Lenoir, V.; Glehen, O.; Thouvenot, D.; Malcus, C.; Favrot, M.; Dumontet, C.; Lombard-Bohas, C.; Garbit, F.; Gueugniaud, P.Y.; Vignal, J.; Aymard, M.; Touraine Moulin, F.; Roos, M.; Pavirani, A.; Courtney, M.
Hepato-Gastroenterology 46 Suppl. 1: 1268-1273
1999
ISSN/ISBN: 0172-6390 PMID: 10429973 Document Number: 506791
Document emailed within 1 workday
Related Documents
Nakamori, S.; Endo, W.; Ozato, H.; Shibata, T.; Takeda, Y.; Tohno, K.; Hasuike, Y.; Masutani, S.; Morimoto, T.; Doki, Y.; Mori, M.; Monden, M. 2011: Multicenter phase Ii study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(5): 789-792Maruo, H.; Suzuki, K.; Ishikawa, S.; Murakami, T.; Higashi, Y.; Shoji, T.; Yamazaki, M.; Taniguchi, M.; Nishiyama, R. 2014: Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(13): 2583-2586
Villalobos-Pérez, J.J.; Martin-Chapa, M.I.; Cedeira-Hernández, A.; Reyes-Aguilar, G.; Aranda-Michel, J.; Vargas, F.; Sosa, R. 1986: 6th report of the Study Group on cancer of the digestive system Gaceta Medica de Mexico 122(1-2): 49-54
Soma, I.; Hasuike, Y.; Hayashi, N.; Fukuchi, N.; Izawa, H.; Yoshida, T.; Ebisui, C.; Sakita, I.; Fujimoto, T.; Koshino, T.; Izumiyama, K. 2004: A case report--Efficacy of combination therapy to unresectable advanced gall bladder carcinoma--palliative operation, hepatic arterial infusion therapy, and radiation therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(11): 1903-1905
Cantore, M.; Fiorentini, G.; Mambrini, A.; Rabbi, C.; Zamagni, D.; Carlone, N.; Manni, A.; Caudana, R.; Torri, T. 2003: Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase Ii study Journal of Experimental and Clinical Cancer Research: Cr 22(4 Suppl): 59-64
Zhao, M.; Xiao, S.-w.; Yang, J.-x.; Zhang, S.-w.; Lü, Y.-y. 2005: Detection of p53 gene change and serum antibody level in phase Ii clinical trial of ad p53 gene therapy Zhonghua Yi Xue Za Zhi 85(49): 3495-3498
Villalobos, J.J.; Anzures, E.; Rodríguez, L.; Peláez, M.; Olaeta, R.; Vargas, F.; Sosa, R.; Muñoz, L.; Pineda, B.E.; González, M. 1988: Ninth report of the Study Group on Cancer of the Digestive System of the National Academy of Medicine Revista de Gastroenterologia de Mexico 53(2): 103-109
Kjaer, M. 1988: Mistletoe therapy of metastasizing renal cancer. a phase Ii study Ugeskrift for Laeger 150(32): 1923-1928
Bernstein, I.D.; Evans, A.E.; Finklestein, J.; Klemperer, M.; Hittle, R.; Leikin, S.; Hammond, G.D. 1978: Phase II study of the failure of vincristine and bleomycin for previously treated children with metastatic neuroblastoma: a report from the Childrens Cancer Study Group Cancer Treatment Reports 62(8): 1201-1202
Sugimoto, K.; Ohzato, H.; Tomita, N.; Tamura, S.; Aihara, T.; Okamura, S.; Miki, H.; Nakata, K.; Kim, C.; Takiuchi, D.; Okada, K.; Takatsuka, Y. 2005: Two cases of successful local control with intermittent hepatic arterial infusion therapy using 5-FU and external radiation therapy for unresectable advanced gall bladder cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(11): 1855-1858
Ettinger, D.S.; Order, S.E.; Wharam, M.D.; Parker, M.K.; Klein, J.L.; Leichner, P.K. 1982: Phase I-Ii study of isotopic immunoglobulin therapy for primary liver cancer Cancer Treatment Reports 66(2): 289-297
Stewart, J.A. 1988: Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists Seminars in Oncology 15(2 Suppl. 2): 10-16
Tong, X.W.; Engehausen, D.G.; Kaufman, R.H.; Agoulnik, I.; Contant, C.; Freund, C.T.; Oehler, M.K.; Kim, T.E.; Hasenburg, A.; Woo, S.L.; Kieback, D.G. 1998: Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy Anticancer Research 18(2a): 713-718
Oikawa, Y.; Takahashi, M.; Takahashi, S.; Matsumoto, S.; Kenno, S.; Noguchi, K.; Kakisaka, T.; Tahara, M.; Yamagami, H.; Ishizu, H. 2016: Analysis of Oxaliplatin Combination Therapy for Unresectable or Recurrent Gastric Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(12): 1579-1581
Nagata, N.; Kimura, M.; Hirabayashi, N.; Tuburaya, A.; Murata, T.; Kondo, K.; Fukuda, Y.; Kobayashi, M.; Miyashita, Y.; Nakao, A.; Sakamoto, J. 2008: Phase Ii study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer Hepato-Gastroenterology 55(86-87): 1846-1850
Lehnert, M.; Biffl, G.; Wascher, H.; Jordis-Lohausen, K.; Wählby, S. 1986: A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase Ii study Seminars in Oncology 13(1 Suppl 1: 32-34
Ibayashi, J. 1984: Cooperative phase Ii study of releasing tegafur (SF-SP) against advanced digestive cancers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(7): 1414-1419
Wang, J.H. 1992: Hepatic arterial infusion chemotherapy plus embolization for unresectable liver cancer--a report on 40 patients Zhonghua Zhong Liu Za Zhi 14(4): 276-279
Arakawa, S.; Horiguchi, A.; Tomishige, H.; Kawabe, N.; Nagata, H.; Ishihara, S.; Ito, M.; Asano, Y.; Ito, R.; Isetani, M.; Shimizu, K.; Kamio, K.; Kawai, T.; Yasuoka, H.; Imaeda, Y. 2018: Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(4): 649-651
Kawabata, R.; Kameda, C.; Takata, A.; Yasuyama, A.; Matsumura, T.; Koga, C.; Murakami, M.; Hirota, M.; Noura, S.; Shimizu, J.; Chatani, M.; Imai, Y.; Hasegawa, J. 2017: A Case of Unresectable Advanced Gastric Cancer Treated with Palliative Radiation Therapy for Massive Bleeding Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(12): 1653-1655